Curia to Acquire US-Based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered into a definitive agreement to acquire LakePharma Inc., a privately held biologics drug discovery, clinical research, development and manufacturing organization with operations in California, Massachusetts, and Texas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005230/en/
Established in 2009 in the Bay Area, LakePharma applies its range of technology platforms to advance projects from discovery to development to manufacturing, namely cell-line development, bioexpression systems and viral vector production systems. Almost a quarter of its employees hold Ph.D.s, bringing expertise in all major biologics segments: mammalian, microbial, plasmid DNA, mRNA, monoclonal antibodies, and viral vector, including cell and gene therapy. LakePharma has contributed to the development of more than 200 therapeutic or diagnostic products and served more than 1,500 customers, including 22 of the top 25 global biopharmaceutical companies.
After the transaction close, the combined company will provide deep expertise in both large and small molecules from drug discovery through drug substance manufacturing, sterile injectable formulation and fill-finish production. LakePharma’s six facilities and 235 employees will join with Curia’s 21 sites and more than 3,100 employees to offer clients an end-to-end partnership in drug discovery, formulation and process development as well as drug substance and drug product clinical and commercial manufacturing. Curia recently announced it has also signed a definitive agreement to acquire Integrity Bio, a privately held formulation and fill-finish organization headquartered in Camarillo, California.
“LakePharma will expand our integrated approach to provide biotech and pharmaceutical companies with small and large molecule research, development and manufacturing solutions,” said Curia Chairman & CEO John Ratliff. “Funding and innovation in the biotech sector remains strong. Our combined capabilities will enable us to partner with our customers by seamlessly providing LakePharma’s multi-modality innovation and speed along with fill-finish solutions from Curia. Our agreements with LakePharma and Integrity Bio demonstrate our commitment to expanding and deepening our biologics capabilities to help our customers advance from curiosity to cure.”
Hua Tu, Ph.D., founder and CEO of LakePharma, said: “LakePharma is delighted to join the Curia family. Over the last 12 years, we have built a strong brand as 'The Biologics Company,' a talented and dedicated employee team, and a loyal and supportive client base. We are excited to join Curia’s global network, including commercial manufacturing capabilities, in delivering end-to-end integrated biologics solutions to our pharma and biotech clients.”
RBC Capital Markets, LLC is serving as exclusive financial adviser to Curia and Nelson Mullins Riley & Scarborough LLP is serving as Curia’s legal counsel. Goldman Sachs & Co. LLC is serving as financial adviser to LakePharma, and Fenwick & West LLP is serving as LakePharma’s legal counsel. The transaction, which is subject to standard and customary closing conditions, is expected to close in the third quarter. Terms of the agreement have not been disclosed.
About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,100 employees at 21 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.
About LakePharma
LakePharma is a U.S.-based biologics CRDMO with operations in California, Texas, and Massachusetts. This biotech company specializes in the production and evaluation of DNA vectors, viral vectors, cell lines, proteins, antibodies, mRNA and conjugates while providing integrated solutions bridging discovery, engineering, development, and GMP manufacturing. LakePharma has contributed to the development of 200+ therapeutic or diagnostic products and strives to develop hundreds more. Learn more at www.LakePharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005230/en/
Contact information
Corporate:
Sue Zaranek
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com
Media Communications:
Debra Harrsch
Brandwidth Solutions LLC
+1 215 997 8575
dharrsch@bwsmarketing.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cannatrol, Creators of Breakthrough Postharvest Cannabis Technology, Receive Two European Patent Approvals25.4.2024 14:03:00 CEST | Press release
Cannatrol, the creators of the only total dry, cure and store system for the cannabis industry, announced today the approval of two European patents for its Vaportrol® Technology, protecting the proprietary technology throughout the European Union. “As the European cannabis industry grows, demand for precision drying, curing and storage technologies continues to expand,” said David Sandelman, co-founder, COO and CTO of Cannatrol. “Cannatrol’s proven environmental-control system ensures top-quality cannabis through a repeatable, consistent process, and it’s appropriate for any scale of cultivation, from large-scale greenhouse production to home growers.” Cannatrol’s patented postharvest technology is proven to increase yields and curing efficiency, and delivers on average 16% higher terpene retention when compared to traditional drying and curing methods, according to independent testing by The Cannabis Research Coalition. Throughout drying, curing and storage, the environment will stay
Visa Joins AWS Partner Network to Help Simplify Global Digital Payments25.4.2024 14:00:00 CEST | Press release
Visa (NYSE: V), a world leader in global digital payments, announced today it has joined the AWS Partner Network (APN), a global community that leverages AWS technologies, programs, expertise, and tools to build solutions and services for customers. Visa’s presence in the APN will help enable its partners and clients, including cloud-native fintechs, to access and integrate select Visa services more efficiently. Global Payments Simplified Visa is committed to making transactions faster, easier and more secure for all players in the payments ecosystem. Visa will make select payment services available in the AWS Marketplace, which has more than 300,000 global customers and thousands of software listings. By making its services available in AWS, Visa is meeting its clients where they are. One of the first services to be available is Visa Cross-Border Solutions, which assists in streamlining the process of sending and receiving money globally and holding multiple currencies. This strategic
Edgio Releases Client-Side Protection to Help Protect Users’ Data Against Malicious Scripts25.4.2024 14:00:00 CEST | Press release
Edgio, the platform of choice for security, speed and simplicity at the edge, today announced the release of its Client-Side Protection solution. Designed to monitor scripts and APIs on the browser-side to prevent malicious code from exfiltrating sensitive customer data, Edgio Client-Side Protection allows teams to gain full visibility on client-side vulnerabilities, achieve full control over all first- and third-party resources and maintain the latest compliance requirements. Payment Card Industry (PCI) Data Security Standard (DSS) v4.0 represents the latest global standards for protecting payment data against sophisticated cyber attacks. PCI DSS v4.0 reflects the latest needs of the payments industry as threats evolve, including damaging Magecart attacks, a type of digital credit card skimming. With Magecart skimmers spotted in over 2 million websites, organizations must prioritize proactively protecting customer data based on a comprehensive understanding of the scripts and external
Baseline Enrollment Completed for AMRA Medical and Linköping University’s Landmark Liver Disease Study25.4.2024 13:50:00 CEST | Press release
AMRA Medical, a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms, in collaboration with Linköping University, is pleased to announce the completion of baseline enrollment for the innovative ACCESS-ESLD (A Rapid, Non-invasive, Clinical Surveillance for CachExia, Sarcopenia, Portal HypertenSion, and Hepatocellular Carcinoma in End-Stage Liver Disease) study. The nationally-comprised study population includes 150 liver cirrhosis patients aged 18 and up, with no liver transplant history or contraindications to performing an MRI examination, enrolled from one of three Swedish liver care clinics located in Linköping, Eksjö, or Jönköping. Over a duration of 2 years, patients will be assessed every 6 months with a comprehensive clinical examination and a whole-body MRI examination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240425020
Geopolitical Unrest Generates an Onslaught of DDoS Attacks, According to the Latest NETSCOUT Threat Intelligence Report25.4.2024 12:05:00 CEST | Press release
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) today released findings from its 2H2023 DDoS Threat Intelligence Report that dissects trends and attack methodologies adversaries use against service providers, enterprises, and end-users. The information cited in the report is gathered from NETSCOUT’s unparalleled internet visibility at a global scale, collecting, analyzing, prioritizing, and disseminating data on DDoS attacks from 214 countries and territories, 456 vertical industries, and more than 13,000 Autonomous System Numbers (ASNs). Driven by tech-savvy and politically motivated hacktivist groups and an increase in DNS water torture attacks, NETSCOUT observed more than 7 million DDoS attacks in the second half of 2023, representing a 15% increase from the first half. Hacktivism Increases Ten-Fold DDoS (Distributed Denial-of-Service) hacktivism transcended geographic borders during the past year, exemplifying a shift in the global security landscape. Groups like NoName057(016) and Anonymous
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom